| # | Title | Journal | Year | Citations |
|---|
| 1 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management | Nature Reviews Gastroenterology and Hepatology | 2020 | 1,155 |
| 2 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) | European Journal of Immunology | 2019 | 766 |
| 3 | Mutations and prognosis in primary myelofibrosis | Leukemia | 2013 | 653 |
| 4 | Mediterranean diet and multiple health outcomes: an umbrella review of meta-analyses of observational studies and randomised trials | European Journal of Clinical Nutrition | 2018 | 628 |
| 5 | NMR Spectroscopy for Metabolomics Research | Metabolites | 2019 | 627 |
| 6 | Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies | Critical Reviews in Food Science and Nutrition | 2017 | 626 |
| 7 | Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis | Blood | 2014 | 575 |
| 8 | Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome | Blood | 2018 | 573 |
| 9 | Broad targeting of resistance to apoptosis in cancer | Seminars in Cancer Biology | 2015 | 535 |
| 10 | COVID-19-Related Mental Health Effects in the Workplace: A Narrative Review | International Journal of Environmental Research and Public Health | 2020 | 493 |
| 11 | Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread | Nature Microbiology | 2019 | 476 |
| 12 | Sustained proliferation in cancer: Mechanisms and novel therapeutic targets | Seminars in Cancer Biology | 2015 | 468 |
| 13 | Consumption of ultra-processed foods and health status: a systematic review and meta-analysis | British Journal of Nutrition | 2021 | 463 |
| 14 | Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent | Journal of Clinical Investigation | 2020 | 424 |
| 15 | Mapping and predicting mortality from systemic sclerosis | Annals of the Rheumatic Diseases | 2017 | 410 |
| 16 | The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion | Blood Cancer Journal | 2018 | 404 |
| 17 | Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis | Leukemia | 2016 | 393 |
| 18 | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Blood | 2013 | 383 |
| 19 | Broad targeting of angiogenesis for cancer prevention and therapy | Seminars in Cancer Biology | 2015 | 375 |
| 20 | Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis | JAMA Oncology | 2015 | 362 |
| 21 | COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs | Turkish Journal of Medical Sciences | 2020 | 351 |
| 22 | Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia | Blood | 2014 | 346 |
| 23 | Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial | Lancet, The | 2018 | 345 |
| 24 | Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis | Blood | 2014 | 340 |
| 25 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update | Annals of the Rheumatic Diseases | 2023 | 335 |
| 26 | Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis | Journal of Scleroderma and Related Disorders | 2017 | 321 |
| 27 | Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature | International Journal of Molecular Sciences | 2019 | 317 |
| 28 | Sarcopenia: an overview | Aging Clinical and Experimental Research | 2017 | 315 |
| 29 | Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2 | Science Advances | 2020 | 312 |
| 30 | Cancer prevention and therapy through the modulation of the tumor microenvironment | Seminars in Cancer Biology | 2015 | 285 |
| 31 | The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients | Leukemia | 2014 | 263 |
| 32 | Male Oxidative Stress Infertility (MOSI): Proposed Terminology and Clinical Practice Guidelines for Management of Idiopathic Male Infertility | World Journal of Men?s Health | 2019 | 256 |
| 33 | High‐Throughput Metabolomics by 1D NMR | Angewandte Chemie - International Edition | 2019 | 254 |
| 34 | The correlation between stress and economic crisis: a systematic review | Neuropsychiatric Disease and Treatment | 2016 | 249 |
| 35 | COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) | Blood Transfusion | 2020 | 247 |
| 36 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia | Blood Advances | 2016 | 243 |
| 37 | Physical activity and exercise as countermeasures to physical frailty and sarcopenia | Aging Clinical and Experimental Research | 2017 | 243 |
| 38 | Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study | Lancet Haematology,the | 2017 | 243 |
| 39 | Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group | Leukemia | 2015 | 242 |
| 40 | A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis | Leukemia | 2017 | 242 |
| 41 | Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 239 |
| 42 | Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition | Seminars in Cancer Biology | 2015 | 231 |
| 43 | Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes | Journal of Allergy and Clinical Immunology: in Practice | 2017 | 229 |
| 44 | Designing a broad-spectrum integrative approach for cancer prevention and treatment | Seminars in Cancer Biology | 2015 | 220 |
| 45 | Extrahepatic manifestations of chronic hepatitis C virus infection | Digestive and Liver Disease | 2014 | 218 |
| 46 | GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis | Leukemia | 2018 | 213 |
| 47 | Altered Immunoregulation in Rheumatoid Arthritis: The Role of Regulatory T Cells and Proinflammatory Th17 Cells and Therapeutic Implications | Mediators of Inflammation | 2015 | 208 |
| 48 | Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study | Lancet Oncology, The | 2017 | 205 |
| 49 | ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study | Annals of the Rheumatic Diseases | 2017 | 199 |
| 50 | Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) | European Journal of Immunology | 2021 | 198 |
